Personal Information
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
oxfordbio.com
À propos
Internationally renowned Professors David Kerr and Nick La Thangue started OCB from the laboratories of the University of Oxford in 2012. Their aim was to discover and develop biomarkers using screening platforms to advance personalised medicine within oncology, specifically colorectal cancer and its treatments.
Since then, we have built a world class development team consisting of industry professionals, leading scientists and oncologists, retaining strong links to Oxford University. Together we have developed pioneering biomarker technology products that put each individual patient at the centre of cancer treatment.
Mots-clés
oncology
chemotherapy
science
cancer
dna
colorectal cancer
colorectalcancer
biomarkers
medicine
Tout plus